特发性肺纤维化:2023年进展综述
本文为2023年发表的简明临床综述,围绕特发性肺纤维化(IPF)的诊断、流行病学、自然病史和治疗,结合新知识与最新临床实践指南进行更新。综述指出IPF患病率近二十年上升,尤其65岁以上人群,抗纤维化治疗可减缓疾病进展,定期临床监测对评估病情和指导管理至关重要。
要点
- IPF患病率近二十年上升,尤其65岁以上人群。
- 抗纤维化治疗可减缓IPF疾病进展。
- 定期监测症状、生理和影像以评估进展并指导管理。
核心结论
- 抗纤维化治疗可减缓IPF疾病进展,定期临床监测对评估自然病程和指导管理至关重要。
- 需要更多研究确定IPF早期发现能否改善患者结局。
研究设计与样本
- 本文为简明临床综述,检索范围未在原文中报告。
主要发现
- IPF患病率近二十年上升,尤其65岁以上人群。
- IPF患者个体病程和疾病进展速度常不可预测且异质。
- 抗纤维化治疗可减缓肺功能下降速度。
- 合并症可能增加症状负担并影响生存。
关键数值与推荐
- 定期临床监测评估疾病进展依据症状加重、生理参数和/或影像学特征。
- 及时识别需额外治疗考虑的并发症和合并症。
- 及时考虑合适患者转介姑息治疗和肺移植。
临床怎么用
- 对IPF患者定期监测症状、生理参数和影像学以评估疾病进展。
- 及时识别并发症和合并症并考虑额外治疗。
- 合适患者及时转介姑息治疗和肺移植。
局限性
- 需要更多研究确定IPF早期发现能否改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by worsening respiratory symptoms and physiological impairment. Increasing awareness of the clinical manifestations of IPF, more widespread use of computed tomography scans and other potential factors have contributed to a rising prevalence of IPF over the last two decades, especially among people over the age of 65 years. Significant advances in the understanding of the pathobiology of IPF have emerged, and multiple genetic and nongenetic contributors have been identified. The individual patient course and the rate of disease progression in IPF are often unpredictable and heterogeneous. The rate of lung function decline is further modified by treatment with antifibrotic therapies, which have been shown to slow down disease progression. The presence of comorbid conditions may increase symptom burden and impact survival. Clinical monitoring at regular intervals to assess for disease progression by worsening symptoms, physiological parameters and/or radiological features is essential to assess the natural disease course and to guide further management, including prompt detection of complications and comorbid conditions that warrant additional treatment considerations, and timely consideration of referral to palliative care and lung transplantation for the appropriate patient. More studies are needed to determine whether early detection of IPF might improve patient outcomes. The purpose of this concise clinical review is to provide an update on IPF diagnosis, epidemiology, natural history and treatment in the context of new knowledge and latest clinical practice guidelines.
引用
- Podolanczuk AJ, Thomson CC, Remy-Jardin M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J. 2023. PMID: 36702498. doi:10.1183/13993003.00957-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。